Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan.
Emerg Infect Dis
; 28(7): 1518-1520, 2022 07.
Article
em En
| MEDLINE
| ID: mdl-35468049
ABSTRACT
Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitorâassociated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 1
/
Nivolumabe
/
Inibidores de Checkpoint Imunológico
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
COVID-19
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article